Monkey Pox Treatment Market Report 2026

The monkey pox treatment market size has grown rapidly in recent years. It will grow from $0.1 billion in 2025 to $0.11 billion in 2026 at a compound annual growth rate (CAGR) of 13%. The growth in the historic period can be attributed to previous outbreaks in endemic regions, limited access to vaccines, delayed diagnosis due to low awareness, reliance on supportive care, global spread during 2022 outbreak.

The monkey pox treatment market size is expected to see rapid growth in the next few years. It will grow to $0.18 billion in 2030 at a compound annual growth rate (CAGR) of 13%. The growth in the forecast period can be attributed to expansion of antiviral pipeline, rising global vaccination initiatives, increased funding for infectious disease research, adoption of improved diagnostic tools, growing government preparedness programs. Major trends in the forecast period include expansion of precision-based antiviral development, adoption of AI-powered outbreak forecasting models, growth of digital tracking systems for case monitoring, increasing use of iot-enabled disease surveillance networks, rising demand for sustainable vaccine production processes.

The rising prevalence of zoonotic infections is expected to drive the growth of the monkeypox treatment market in the coming years. Zoonotic infections are diseases transmitted from animals to humans through direct contact with infected animals, contaminated environments, or vectors. Increased human-animal interactions, along with climate change expanding the habitats of disease vectors, have heightened the risk of zoonotic infections. Monkeypox treatments are used to manage zoonotic mpox by targeting the virus and alleviating symptoms in humans and potentially infected animals. For example, in August 2024, according to a report by the UK Health Security Agency, a UK-based government organization, there were 3,732 confirmed monkeypox cases in the UK, rising to 3,753 cases in 2023. Therefore, the increasing prevalence of zoonotic infections is fueling the monkeypox treatment market.

Key companies in the monkeypox treatment market are focusing on innovative products, such as small-molecule antivirals, to strengthen global preparedness and stockpiling capacity. Small-molecule antivirals inhibit specific viral proteins to prevent viral replication and spread within the body and can be stored long-term, making them suitable for emergency response. For instance, in January 2025, SIGA Technologies, a US-based pharmaceutical company, received approval in Japan for TEPOXX (tecovirimat 200 mg capsules), the first antiviral approved to treat orthopoxviruses in the country. TEPOXX demonstrated a strong safety profile in 15 clinical trials involving over 800 healthy volunteers, showed effective pharmacokinetics, and reduced viral load and mortality in preclinical animal models. The drug inhibits the VP37 protein on the virus surface, preventing viral exit from infected cells and allowing the immune system to clear the infection. SIGA partnered with Japan Biotechno Pharma as the exclusive distributor to build Japan’s strategic national stockpile of TEPOXX.

In August 2024, Bilthoven Biologicals, a Netherlands-based vaccine and biopharmaceutical provider, partnered with Tonix Pharmaceuticals to accelerate the development of TNX-801, a potential vaccine for preventing monkeypox, smallpox, and other infectious diseases. Tonix Pharmaceuticals is a US-based pharmaceutical company focused on developing monkeypox treatment vaccines.

Major companies operating in the monkey pox treatment market are Merck & Co Inc, Sanofi S A, Gilead Sciences Inc, BioNTech SE, Moderna Inc, Novavax Inc, Emergent BioSolutions Inc, Bavarian Nordic A S, SIGA Technologies Inc, Tonix Pharmaceuticals Holding Corp, Chimerix Inc, Emcure Pharmaceuticals Ltd, VBI Vaccines Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, GeoVax Labs Inc, Zydus Cadila Ltd, Serum Institute of India Pvt Ltd, Biological E Ltd, Dr Reddy’s Laboratories Ltd, Hester Bioscience Ltd, Indian Immunologicals Ltd, Reliance Life Sciences Pvt Ltd, Takeda Pharmaceuticals Co Ltd, KM Biologics Co Ltd, Meridian Bioscience Inc, NanoViricides Inc.

North America was the largest region in the monkey pox treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monkey pox treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the monkey pox treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on pharmaceutical ingredients, vaccines, and medical devices have increased production and procurement costs for monkeypox treatments, particularly in regions dependent on imports for antivirals and vaccines. The most affected segments include prophylactic vaccines and antiviral agents, with Africa, Asia-Pacific, and South America experiencing the highest cost pressures. However, tariffs have encouraged domestic manufacturing capacity and accelerated regional vaccine development programs, resulting in improved long-term supply resilience.

The monkey pox treatment market research report is one of a series of new reports that provides monkey pox treatment market statistics, including monkey pox treatment industry global market size, regional shares, competitors with a monkey pox treatment market share, detailed monkey pox treatment market segments, market trends and opportunities, and any further data you may need to thrive in the monkey pox treatment industry. This monkey pox treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Monkeypox treatment refers to medical interventions and therapies used to manage and relieve the symptoms of monkeypox, a viral disease caused by the monkeypox virus. It includes a variety of therapeutic and supportive approaches aimed at reducing disease severity and improving patient outcomes.

The main types of monkeypox treatment include prophylactic vaccines and therapeutics. Prophylactic vaccines are designed to prevent monkeypox infection by activating the immune system to recognize and combat the virus, particularly in high-risk populations and during outbreaks to control its spread. The dosage forms include solid, liquid, and semisolid preparations, with routes of administration such as oral, topical, and parenteral. Distribution channels include retail pharmacies, hospital pharmacies, and online pharmacies.

The monkey pox treatment market consists of sales of treatment products such as antiviral medications, vaccine administration devices, supportive care products, infection control supplies, and Reagents and assays for monkeypox research and diagnostic development. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.